CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 70 enrolled
Drug / intervention
Nintedanib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02572752
NCT02572752Phase 1Completed
CompareCT.gov

Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects

Boehringer Ingelheim·interventional·Posted Oct 9, 2015·Updated Jan 5, 2017

In Brief

A Phase 1 clinical trial evaluating Nintedanib for Healthy. Completed, enrolled 70 participants across 1 site.

Detailed Summary

To establish the bioequivalence of 1 soft gelatine capsule containing 200 mg nintedanib compared to 2 soft gelatine capsules containing 100 mg nintedanib

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 9, 2015
Enrollment StartAug 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 10.7 years ago

Interventions

Nintedanibdrug

1 soft gelatine capsule, single dose, oral

Nintedanibdrug

Nintedanib, 2 soft gelatine capsules, single dose, oral

Nintedanibdrug